UNSPSC 51461534: Aralia

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T90W4582DU, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 29372 ss a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Apiales, Family Araliaceae, Genus Aralia L., more commonly known as SPIKENARD or, as here, ARALIA.

Aralia bears the USDA PLANTS Database Identifier ARALI. European Medicines Agency schedules the most commonly-used aralia variety [in medicine] in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB40581, SUB46029, and SUB46030.

UNSPSC 51461534 Aralia, a Commodity code, encompasses botanical plant products and derivatives supplied to state and local government facilities. State and local governments procure aralia and similar plant materials primarily through cooperative purchasing arrangements that aggregate demand across multiple jurisdictions, bundling them with broader pharmaceutical and over-the-counter product categories to leverage volume discounts and streamline distribution through established wholesaler networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body pursuing this code currently. MMCAP issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) certification requirements. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The evaluation emphasizes price competitiveness (75 percent weight), fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and data format requirements (5 percent). Vendors are required to maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and pay a 3 percent administrative fee on all contract purchases.